WD-40 Co.: A Beloved Brand Priced Well Beyond Its Cash Flows

TradeApes classifies WD-40 as Overvalued with High confidence. The composite fair value of $108.46 sits 48% below the current price of $207.57, and the agreement across primary methods is unusually tight — both DCF approaches converge at $118.17 and the multiples method lands at $98.75, producing low method dispersion. The primary counterpoint is genuine: WD-40 is a high-ROIC compounder with durable brand economics, and the market has historically awarded exactly this kind of business a structural premium. But even granting that premium, the gap between price and estimated intrinsic value is large enough — and consistent enough across methods — to justify a high-confidence overvaluation call.

What the Price Is Betting On

This is where the analysis sharpens into something concrete. The implied FCF growth rate the current price requires exceeds the model's plausibility bounds — the engine's out-of-bounds flag means only the directional conclusion is supportable: the price demands cash-flow growth dramatically above the model's normalized base case of roughly 18%. On a revenue base of approximately $601 million and free cash flow of $71.8 million, that normative growth rate is already a respectable assumption. What the market price requires goes well beyond it.

Translated to plain English: WD-40's stock is priced as though the company will compound its free cash flows at a rate that would be exceptional even for a high-growth technology firm — applied to a specialty-chemicals business with a mature product portfolio. For that expectation to be correct, WD-40 would need to dramatically accelerate its monetization of the brand globally, sustain or expand already-elevated margins, and do so against a backdrop of rising input costs that are endemic to the chemicals sector. None of that is impossible; none of it is priced with any margin of error.

The Valuation Fulcrum

The valuation turns primarily on two variables: the normalized FCF growth trajectory and the WACC applied to discount it (11.95%). At that cost of capital, terminal growth assumed at 4.0% is reasonable for a brand-led consumer staples-adjacent business — it is not the source of controversy. The controversy is entirely on the growth side. The ~$108 composite fair value implies the market is paying roughly 1.9× estimated intrinsic value, and that premium is only justifiable if realized cash-flow growth closes a very wide gap, very quickly, and is then sustained at elevated rates into perpetuity. The price effectively bets on WD-40 re-rating its growth profile in a structurally meaningful way.

Financial Strength

WD-40's financial health is genuinely solid — the 66/100 health score and "healthy" label are supported by the signal data in a meaningful way. The most important strengths are all variations on the same theme: ROIC is high, improving, and well above the cost of capital. A business that consistently earns returns above its WACC is, by definition, creating economic value with every dollar it deploys. That is a real, durable quality and it explains much of the market's willingness to pay a premium.

The concern side of the ledger is equally coherent. Free-cash-flow yield at this price is thin — $71.8 million of FCF against a market cap implying well over $2.7 billion in equity value produces a FCF yield in the low-to-mid single digits at best. EV/EBITDA sits at 26.7×, flagged as a concern relative to sector peers. The PEG concern reflects the same tension: the earnings multiple is rich relative to achievable growth rates. These concerns are not signs of a distressed or deteriorating business; they are signs of a healthy business priced for perfection.

Cash and securities of $59.1 million on $601 million in revenue is modest but not alarming for a mature, asset-light chemical brand with strong recurring cash generation. Liquidity is not the risk here.

How the Market Values It

The peer context makes the premium explicit. WD-40 trades at price-to-book and price-to-tangible-book ratios in the 95th percentile of its 115-company peer universe — investors already assign a near-maximum brand and franchise premium relative to comparable businesses. EV/EBITDA at the 79th percentile confirms the picture: richer than roughly four-fifths of peers on an enterprise-value basis. A company deserving a top-quintile multiple is not unusual for a brand this durable. A company deserving a 95th-percentile book-value multiple while also trading at nearly twice the DCF-estimated intrinsic value is a much harder case to make.

What Could Change the Picture

On the upside: a sustained and structural acceleration in FCF growth — driven by international market penetration, pricing power, or meaningful revenue expansion beyond the current base — would close the gap between current price and fair value. ROIC is already strong; if reinvestment opportunities scaled materially, the valuation math would look different.

On the downside: any compression in operating margins, an increase in the cost of capital (the 11.95% WACC is already moderately elevated), or a deceleration in topline growth that makes the embedded expectations more visibly unreachable could put meaningful pressure on a stock where there is no valuation cushion. At 95th-percentile multiples, there is no room for disappointment.

A re-rating of specialty chemicals or consumer staples multiples more broadly — in either direction — would move this analysis, since much of the premium is sector-sentiment-driven as well as company-specific.

Key Model Inputs

The DCF fair value of $118.17 rests on a WACC of 11.95%, normalized FCF growth of approximately 18%, and a terminal growth rate of 4.0%. The fair value is sensitive to all three, but most sensitive to the FCF growth assumption. The low dispersion across the primary methods — DCF and multiples landing within roughly $20 of each other — means the overvaluation conclusion does not hinge on any single methodology. The composite of $108.46 is a well-supported central estimate, not a fragile outlier from one approach.

TradeApes classification: Overvalued · Confidence: High · Analysis date: 2026-09-05 · Price at generation: $207.57

TradeApes is a research tool, not investment advice.